Evaluation of feasibility and applicability of current EASL-EASD-EASO and DGVS guidelines for diagnosis of Non-Alcoholic Fatty Liver disease in Patients with Type 2 Diabetes mellitus.

Evaluation of feasibility and applicability of current EASL-EASD-EASO and DGVS guidelines for diagnosis of Non-Alcoholic Fatty Liver disease in Patients with Type 2 Diabetes mellitus. - NAFLD-DM2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012281

Enrollment

300

Registered

2017-04-13

Start date

2017-04-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11 K76.0

Interventions

Group 1: conventional ultrasound, liver elastography, laboratory based markers of liver fibrosis and anthropometric measures

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Typ 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: liver transplantation, pregnancy/lactation, malignant disease with restricted life expectancy.

Design outcomes

Primary

Measure	Time frame
Applicability and correlation of non-invasive diagnostic tests (conventional ultrasound, liver elastography, laboratory based markers of liver fibrosis and anthropometric measures) for characterization of Non-Alcoholic Fatty Liver disease (NAFLD).	—

Secondary

Measure	Time frame
Frequency and patient associated factors for incongruous non-invasive NAFLD tests.	—

Countries

Germany

Contacts

Public ContactValentin Blank

Klinik für Gastroenterologie und Rheumatologie

blank@medizin.uni-leipzig.de03419712200

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026